



**Disclosure Statement Pursuant to the Pink Basic Disclosure Guidelines**  
**Aoxing Pharmaceutical Company, Inc.**

624 Tyvola Rd, Suite 103 #186, Charlotte NC 28217  
+1 704 – 951 – 7087  
[www.aoxginc.com](http://www.aoxginc.com)  
[info@aoxginc.com](mailto:info@aoxginc.com)  
SIC: 2834

## Annual Report

For the period ending [6/30/23] (the “Reporting Period”)

### **Outstanding Shares**

The number of shares outstanding of our Common Stock was:

76,209,195 as of 6/30/23

76,209,195 as of 3/31/23

### **Shell Status**

Indicate by check mark whether the company is a shell company (as defined in Rule 405 of the Securities Act of 1933, Rule 12b-2 of the Exchange Act of 1934 and Rule 15c2-11 of the Exchange Act of 1934):

Yes: ☒ No: ☐

Indicate by check mark whether the company’s shell status has changed since the previous reporting period:

Yes: ☐ No: ☒

### **Change in Control**

Indicate by check mark whether a Change in Control<sup>1</sup> of the company has occurred over this reporting period:

Yes: ☐ No: ☒

---

<sup>1</sup> “Change in Control” shall mean any events resulting in:

- (i) Any “person” (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becoming the “beneficial owner” (as defined in Rule 13d-3 of the Exchange Act), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the total voting power represented by the Company’s then outstanding voting securities;
- (ii) The consummation of the sale or disposition by the Company of all or substantially all of the Company’s assets;
- (iii) A change in the composition of the Board occurring within a two (2)-year period, as a result of which fewer than a majority of the directors are directors immediately prior to such change; or
- (iv) The consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its parent) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation.

**1) Name and address(es) of the issuer and its predecessors (if any)**

In answering this item, provide the current name of the issuer any names used by predecessor entities, along with the dates of the name changes.

The current name of the issuer is "Aoxing Pharmaceutical Company, Inc."

The issuer's name was "China Aoxing Pharmaceutical Co., Inc." until March 2010.

The issuer's name was "Central American Equities Corp." until July 2006.

The state of incorporation or registration of the issuer and of each of its predecessors (if any) during the past five years; Please also include the issuer's current standing in its state of incorporation (e.g. active, default, inactive):

As of August 11<sup>th</sup>, 2023, the issuer is active & in good standing with the state of Florida.

Describe any trading suspension orders issued by the SEC concerning the issuer or its predecessors since inception:

N/A

List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

Subsequent to the end of the reporting period on August 11th 2023, the Custodian increased the common Authorized Shares to 750,000,000, the preferred Authorized Shares to 10,000,000, and amended par value of both classes to .0001. And on September 19<sup>th</sup> 2023, the Custodian issued to himself 265,000,000 common shares for corporate revival services. The Company plans to acquire an operating business via reverse merger.

The address(es) of the issuer's principal executive office:

Aoxing Pharmaceutical Company, Inc. 624 Tyvola Rd, Suite 103 #186, Charlotte NC 28217

The address(es) of the issuer's principal place of business:

☒ *Check if principal executive office and principal place of business are the same address:*

\_\_\_\_\_

Has the issuer or any of its predecessors been in bankruptcy, receivership, or any similar proceeding in the past five years?

No: ☐ Yes: ☒ If Yes, provide additional details below:

\_\_\_\_\_

On June 28<sup>th</sup> 2023, the Eleventh Judicial Circuit Court in Miami-Dade County, Florida, entered an Order appointing David Duarte as Custodian of Aoxing Pharmaceutical Company, Inc. (case number: 2022-021295-CA-01). Pursuant to the order, the Custodian may take any actions which are reasonable, prudent, or for the benefit of the Company and its shareholders including but not limited to, reinstating the Company with the state of Florida, holding a shareholders meeting, filing of disclosures with OTC Markets, filing of tax returns, disclosure of capital structure and/or business plan, and to exercise the corporate powers of the Company and its board of directors or officers.

**2) Security Information**

**Transfer Agent**

Name: Olde Monmouth Stock Transfer Co., Inc.  
Phone: (732) 872-2727  
Email: matt@oldemonmouth.com  
Address: 200 Memorial Pkwy, Atlantic Heights, NJ 07716

**Publicly Quoted or Traded Securities:**

*The goal of this section is to provide a clear understanding of the share information for its publicly quoted or traded equity securities. Use the fields below to provide the information, as applicable, for all outstanding classes of securities that are publicly traded/quoted.*

Trading symbol:	AOXG
Exact title and class of securities outstanding:	Common
CUSIP:	03740A106
Par or stated value:	.001
Total shares authorized:	200,000,000 as of date: 6/30/23
Total shares outstanding:	76,209,195 as of date: 6/30/23
Total number of shareholders of record:	289 as of date: 6/30/23

*All additional class(es) of publicly quoted or traded securities (if any):*

Trading symbol:	_____
Exact title and class of securities outstanding:	_____
CUSIP:	_____
Par or stated value:	_____
Total shares authorized:	_____ as of date: _____
Total shares outstanding:	_____ as of date: _____
Total number of shareholders of record:	_____ as of date: _____

Trading symbol:	_____
Exact title and class of securities outstanding:	_____
CUSIP:	_____
Par or stated value:	_____
Total shares authorized:	_____ as of date: _____
Total shares outstanding:	_____ as of date: _____
Total number of shareholders of record:	_____ as of date: _____

**Other classes of authorized or outstanding equity securities:**

*The goal of this section is to provide a clear understanding of the share information for its other classes of authorized or outstanding equity securities (e.g. preferred shares). Use the fields below to provide the information, as applicable, for all other authorized or outstanding equity securities.*

Exact title and class of the security:	<u>Preferred Stock</u>	
CUSIP (if applicable):		
Par or stated value:	<u>.001</u>	
Total shares authorized:	<u>1,000,000</u>	<u>as of date: 6/30/23</u>
Total shares outstanding (if applicable):	<u>0</u>	<u>as of date: 6/30/23</u>
Total number of shareholders of record (if applicable):		<u>as of date:</u>

### **Security Description:**

*The goal of this section is to provide a clear understanding of the material rights and privileges of the securities issued by the company. Please provide the below information for each class of the company's equity securities, as applicable:*

**1. For common equity, describe any dividend, voting and preemption rights.**

Each common share receives one vote. There are no dividend or preemption rights.

**2. For preferred stock, describe the dividend, voting, conversion, and liquidation rights as well as redemption or sinking fund provisions.**

N/A

**3. Describe any other material rights of common or preferred stockholders.**

N/A

**4. Describe any material modifications to rights of holders of the company's securities that have occurred over the reporting period covered by this report.**

N/A

### **3) Issuance History**

The goal of this section is to provide disclosure with respect to each event that resulted in any changes to the total shares outstanding of any class of the issuer's securities **in the past two completed fiscal years and any subsequent interim period**.

Disclosure under this item shall include, in chronological order, all offerings and issuances of securities, including debt convertible into equity securities, whether private or public, and all shares, or any other securities or options to acquire such securities, issued for services. Using the tabular format below, please describe these events.

#### **A. Changes to the Number of Outstanding Shares**

Indicate by check mark whether there were any changes to the number of outstanding shares within the past two completed fiscal years:

No: ☐ Yes: ☒ (If yes, you must complete the table below)

**Example:** A company with a fiscal year end of December 31<sup>st</sup>, in addressing this item for its Annual Report, would include any events that resulted

Shares Outstanding as of Second Most Recent Fiscal Year End: <u>Opening Balance</u> Date <u>6/30/22</u> Common: <u>76,209,195</u> Preferred: <u>0</u>			*Right-click the rows below and select "Insert" to add rows as needed.						
Date of Transaction	Transaction type (e.g., new issuance, cancellation, shares returned to treasury)	Number of Shares Issued (or cancelled)	Class of Securities	Value of shares issued (\$/per share) at Issuance	Were the shares issued at a discount to market price at the time of issuance? (Yes/No)	Individual/ Entity Shares were issued to. *You must disclose the control person(s) for any entities listed.	Reason for share issuance (e.g. for cash or debt conversion) - OR- Nature of Services Provided	Restricted or Unrestricted as of this filing.	Exemption or Registration Type.
9/19/23	New Issuance	265,000,000	Common	.0001	Yes	David Duarte	Corporate Revival Services	Restricted	Exempt
Shares Outstanding on Date of This Report: <u>Ending Balance</u> <u>Ending Balance:</u> Date <u>11/7/23</u> Common: <u>341,201,195</u> Preferred: <u>0</u>									

in changes to any class of its outstanding shares from the period beginning on January 1, 2021 through December 31, 2022 pursuant to the tabular format above.

Use the space below to provide any additional details, including footnotes to the table above:

**\*Subsequent to the end of reporting period, on Sept 19<sup>th</sup> 2023, the Custodian issued to himself 265,000,000 shares of common stock, par value .0001, for consideration of Corporate Revival Services performed.**

## B. Promissory and Convertible Notes

Indicate by check mark whether there are any outstanding promissory, convertible notes, convertible debentures, or any other debt instruments that may be converted into a class of the issuer's equity securities :

No: ☒ Yes: ☐ (If yes, you must complete the table below)

Date of Note Issuance	Outstanding Balance (\$)	Principal Amount at Issuance (\$)	Interest Accrued (\$)	Maturity Date	Conversion Terms (e.g. pricing mechanism for determining conversion of instrument to shares)	Name of Noteholder. *You must disclose the control person(s) for any entities listed.	Reason for Issuance (e.g. Loan, Services, etc.)
_____	_____	_____	_____	_____	_____	_____	_____
_____	_____	_____	_____	_____	_____	_____	_____

_____	_____	_____	_____	_____	_____	_____	_____
_____	_____	_____	_____	_____	_____	_____	_____

Use the space below to provide any additional details, including footnotes to the table above:

\_\_\_\_\_

#### 4) Issuer's Business, Products and Services

The purpose of this section is to provide a clear description of the issuer's current operations.  
(Please ensure that these descriptions are updated on the Company's Profile on [www.otcmarkets.com](http://www.otcmarkets.com)).

A. Summarize the issuer's business operations (If the issuer does not have current operations, state "no operations")

Aoxing Pharmaceutical Company, Inc. was previously involved in the development, manufacturing, and marketing of active pharmaceutical ingredients for narcotics and neurological drugs. The company does not have any business operations at this time, but is restructuring for a new business model and plans to acquire an operating company via reverse merger.

B. List any subsidiaries, parent company, or affiliated companies.

None.

C. Describe the issuers' principal products or services.

The company does not currently have any products or services but is restructuring for a new business model.

#### 5) Issuer's Facilities

The goal of this section is to provide a potential investor with a clear understanding of all assets, properties or facilities owned, used or leased by the issuer and the extent in which the facilities are utilized.

In responding to this item, please clearly describe the assets, properties or facilities of the issuer, give the location of the principal plants and other property of the issuer and describe the condition of the properties. If the issuer does not have complete ownership or control of the property (for example, if others also own the property or if there is a mortgage on the property), describe the limitations on the ownership.

If the issuer leases any assets, properties or facilities, clearly describe them as above and the terms of their leases.

The company has no facilities at this time.

#### 6) Officers, Directors, and Control Persons

Using the table below, please provide information, as of the period end date of this report, regarding any officers, or directors of the company, individuals or entities controlling more than 5% of any class of the issuer's securities, or any person that performs a similar function, regardless of the number of shares they own. **If any insiders listed are corporate shareholders or entities, provide the name and address of the person(s) beneficially owning or controlling such corporate shareholders, or the name and contact information (City, State) of an individual representing the corporation or entity in the note section.**

Include Company Insiders who own any outstanding units or shares of any class of any equity security of the issuer.

The goal of this section is to provide an investor with a clear understanding of the identity of all the persons or entities that are

involved in managing, controlling or advising the operations, business development and disclosure of the issuer, as well as the identity of any significant or beneficial shareholders.

Names of All Officers, Directors and Control Persons	Affiliation with Company (e.g. Officer Title /Director/Owner of more than 5%)	Residential Address (City / State Only)	Number of shares owned	Share type/class	Ownership Percentage of Class Outstanding	Names of control person(s) if a corporate entity
<u>David Duarte</u>	<u>CEO, President, Treasurer, Secretary, Director, Court Appointed Custodian</u>	<u>Charlotte, North Carolina</u>	<u>265,500,000</u>	<u>Common</u>	<u>77.8%</u>	<u>See Below (1)</u>
<u>Cade Carter</u>	<u>Consultant</u>	<u>Rosslyn, Virginia</u>	<u>1,156,361</u>	<u>Common</u>	<u>0.34%</u>	<u>See Below (2)</u>

(1) David Duarte was issued 265,000,000 shares of common stock subsequent to the end of the reporting period on 9/19/23 for Corporate Revival Services. He also controls 500,000 shares of common stock purchased on the open market.

(2) Cade Carter owns 1,156,361 shares of common stock purchased on the open market.

## 7) Legal/Disciplinary History

A. Identify whether any of the persons or entities listed above have, in the past 10 years, been the subject of:

1. A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses);

N/A

2. The entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, or banking activities;

N/A

3. A finding or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended, or vacated; or

N/A

4. The entry of an order by a self-regulatory organization that permanently or temporarily barred, suspended, or otherwise limited such person's involvement in any type of business or securities activities.

N/A

B. Describe briefly any material pending legal proceedings, other than ordinary routine litigation incidental to the business, to which the issuer or any of its subsidiaries is a party or of which any of their property is the subject. Include the name of the court or agency in which the proceedings are pending, the date instituted, the principal parties thereto, a description of the factual basis alleged to underlie the proceeding and the relief sought. Include similar information as to any such proceedings known to be contemplated by governmental authorities.

N/A

## 8) Third Party Service Providers

Provide the name, address, telephone number and email address of each of the following outside providers. You may add additional space as needed.

Securities Counsel (must include Counsel preparing Attorney Letters).

Name: Jonathan D. Leinwand  
Address 1: 18305 Biscayne Blvd., Suite 200  
Address 2: Aventura, FL 33160  
Phone: 954-903-7856  
Email: jonathan@jdlpa.com

Accountant or Auditor

Name: N/A  
Firm: N/A  
Address 1: N/A  
Address 2: N/A  
Phone: N/A  
Email: N/A

Investor Relations

Name: N/A  
Firm: N/A  
Address 1: N/A  
Address 2: N/A  
Phone: N/A  
Email: N/A

*All other means of Investor Communication:*

Twitter: @TailoredTickers  
Discord: N/A  
LinkedIn: N/A  
Facebook: N/A  
[Other ] N/A

Other Service Providers

Provide the name of any other service provider(s) that **that assisted, advised, prepared, or provided information with respect to this disclosure statement**. This includes counsel, broker-dealer(s), advisor(s), consultant(s) or any entity/individual that provided assistance or services to the issuer during the reporting period.

Name: Cade Carter  
Firm: Pyrrhic Capital  
Nature of Services: Consulting  
Address 1: \_\_\_\_\_  
Address 2: \_\_\_\_\_  
Phone: \_\_\_\_\_



Email: PyrrhicCapital@gmail.com

**9) Financial Statements**

A. The following financial statements were prepared in accordance with:

- ☐ IFRS  
☒ U.S. GAAP

B. The following financial statements were prepared by (name of individual)<sup>2</sup>:

Name: **Cade Carter**

Title:

Relationship to Issuer: **Consultant**

Describe the qualifications of the person or persons who prepared the financial statements:

**Has prepared quarterly and annual reports in the past that resulted in the companies in question attaining pink current status.**

Provide the following financial statements for the most recent fiscal year or quarter. For the initial disclosure statement (qualifying for Pink Current Information for the first time) please provide reports for the two previous fiscal years and any subsequent interim periods.

- a. Audit letter, if audited;
- b. Balance Sheet;
- c. Statement of Income;
- d. Statement of Cash Flows;
- e. Statement of Retained Earnings (Statement of Changes in Stockholders' Equity)
- f. Financial Notes

**Documents C-G are incorporated herein.**

---

<sup>2</sup> The financial statements requested pursuant to this item must be prepared in accordance with US GAAP or IFRS and by persons with sufficient financial skills.

## 10) Issuer Certification

*Principal Executive Officer:*

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles but having the same responsibilities) in each Quarterly Report or Annual Report.

The certifications shall follow the format below:

I, David Duarte certify that:

1. I have reviewed this Disclosure Statement for Aoxing Pharmaceutical Company, Inc.;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

11/7/23 [Date]

 [CEO's Signature]


(Digital Signatures should appear as "/s/ [OFFICER NAME]")

*Principal Financial Officer:*

I, David Duarte certify that:

1. I have reviewed this Disclosure Statement for Aoxing Pharmaceutical Company, Inc.;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

11/7/23 [Date]

 [CFO's Signature]

(Digital Signatures should appear as "/s/ [OFFICER NAME]")

AOXING PHARMACEUTICAL COMPANY, INC.  
Index to Unaudited Consolidated Financial Statements

	Page
Financial Statements	
Unaudited Consolidated Balance Sheets as of June 30, 2023 and June 30, 2022	F-2
Unaudited Statement of Operations for the Twelve Months Ended June 30 2023, and 2022	F-3
Unaudited Consolidated Statements of Stockholders' Deficit for the Periods Ended June 30, 2020, through June 30, 2023	F-4
Unaudited Consolidated Statements of Cash Flows for the Twelve Months Ended June 30, 2023, and 2022	F-5
Unaudited Notes to Financial Statements	F-6

AOXING PHARMACEUTICAL COMPANY, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(UNAUDITED)

	June 30, 2023	June 30, 2022
<b>ASSETS</b>		
Current Assets:		
Cash	\$	\$
<b>TOTAL ASSETS</b>	<b>\$</b>	<b>\$</b>
<b>LIABILITIES AND STOCKHOLDERS' DEFECIT</b>		
Current Liabilities:		
Accounts payable	\$ -	\$ -
Accrued liabilities		
Derivative liability		
Due to related parties		
Notes Payable – convertible net of discount		
<b>Total Current Liabilities</b>		
<b>Stockholders' Deficit</b>		
Preferred Stock, 0.001 par value, 1,000,000 shares authorized on June 30 2023 and 2022	0	0
Common Stock, 0.001 par value, 200,000,000 shares authorized and 76,209,195 shares issued and outstanding on June 30 2023 and 2022	76,209	76,209
Additional Paid-In Capital		
Accumulated deficit		
Accumulated Other Comprehensive Income		
<b>Total Stockholder's deficit</b>		
<b>TOTAL LIABILITIES &amp; STOCKHOLDERS' DEFICIT</b>	<b>\$ -</b>	<b>\$ -</b>

The accompanying notes are an integral part of these financial statements

F-2

AOXING PHARMACEUTICAL COMPANY,  
INC. CONSOLIDATED STATEMENTS OF OPERATIONS  
(UNAUDITED)

	For the Twelve Months Ended June 30 <sup>th</sup>			
	2023		2022	
Revenue:				
Sales, net	\$	-	\$	-
Cost of sales:		-		-
Gross Profit		-		-
Operating Expense		-		-
General and administrative expenses				
Total Operating Expenses		-		-
Operating Loss		-	\$	-
Other Income (Expense)				
Interest Expense			-	-
Gain on derivative liability		-		-
Total Other Expense		-		-
Net Income (Loss)		-		-
Adjustments		-		-
<b>NET COMPREHENSIVE LOSS</b>	\$	-	\$	-
BASIC AND DILUTED LOSS PER SHARE:				
Net Loss per common share – basic and diluted	\$	-	\$	-
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:				
Basic		76,209,195		76,209,195

The accompanying notes are an integral part of these financial statements  
F-3

CONSOLIDATED STATEMENTS OF CHANGES IN  
STOCKHOLDERS' DEFICIT  
(UNAUDITED)

	Preferred Stock		Common Stock		Additional	Accumulated	
	# Shares	Amount	# Shares	Amount	Paid-In	Capital	Deficit
	TOTAL						
Balances – June 30, 2020	-	-	76,209,195	-	-	-	-
Net Income (Loss)	-	-	-	-	-	-	-
Balances – June 30, 2021	-	-	76,209,195	-	-	-	-
Net Income (Loss)	-	-	-	-	-	-	-
Balances – June 30, 2022	-	-	76,209,195	-	-	-	-
Net Income (Loss)	-	-	-	-	-	-	-
Balances – September 30, 2022	-	-	76,209,195	-	-	-	-
Net Income (Loss)	-	-	-	-	-	-	-
Balances – December 31, 2022	-	-	76,209,195	-	-	-	-
Net Income (Loss)	-	-	-	-	-	-	-
Balances – March 31, 2023	-	-	76,209,195	-	-	-	-
Net Income (Loss)	-	-	-	-	-	-	-
Balances – June 30, 2023	-	-	76,209,195	-	-	-	-

The accompanying notes are an integral part of these financial statements F-4

AOXING PHARMACEUTICAL COMPANY,  
INC. CONSOLIDATED STATEMENT OF CASH FLOWS  
(UNAUDITED)

	For the Twelve Months Ended June 30 <sup>th</sup>	
	2023	2022
<b>Cash Flows from Operating Activities</b>		
Net income (loss)	\$ -	\$ -
Adjustments to reconcile net income (loss) to net cash used in operating activities		
Gains on derivative liability	-	-
Stock-based transaction expense	-	-
Changes in assets and liabilities	-	-
Increase in accrued liabilities	-	-
Decrease in due to related parties	-	-
<b>Net Cash Used in Operating Activities</b>	-	-
<b>Cash Flows from Financing Activities:</b>		
Proceeds from note payables	-	-
<b>Net Cash Provided by Financing Activities</b>	-	-
<b>Foreign Currency Translation</b>	-	-
<b>Net Change in Cash</b>	-	-
<b>Cash and Cash Equivalents – Beginning of Year</b>	-	-
<b>Cash and Cash Equivalents – End of Period</b>	\$ -	\$ -

The accompanying notes are an integral part of these financial statements

F-5

**AOXING PHARMACEUTICAL COMPANY, INC.**  
**NOTES TO UNAUDITED CONSOLIDATE FINANCIAL STATEMENTS**  
**FOR THE TWELVE MONTHS ENDED June 30, 2023**  
**(Unaudited)**

**NOTE 1 – ORGANIZATION AND NATURE OF OPERATIONS**

Aoxing Pharmaceutical Company, Inc. (the “Company,” “we,” “us” or “our”), a Florida corporation, has a fiscal year end of June 30<sup>th</sup> and is listed on the OTC Pink Markets under the trading symbol AOXG. The Company had abandoned its business and failed to take steps to dissolve, liquidate and distribute its assets. It had also failed to meet the required reporting requirements with the Florida Secretary of State, hold an annual meeting of stockholders and pay its annual tax from 2019 to 2022 which resulted in its Florida charter being administratively dissolved. The Company also failed to provide adequate current public information as defined in Rule 144, promulgated under the Securities Act of 1933, and was thus subject to revocation by the Securities and Exchange Commission pursuant to Section 12(k) of the Exchange Act. In November 2022, a shareholder filed a petition for custodianship with the Eleventh Circuit Court, Miami-Dade County, Florida and was appointed as the Custodian of the Company in June 2023. The custodian was not able to recover any of the Company’s accounting records from previous management but was able to get the shareholder information hence the Company’s outstanding common shares were reflected in the equity section of the accompanying unaudited financial statements for the twelve months ended Sept 30, 2023 and 2022.

The company was incorporated in the State of Florida in January 1996 as Central American Equities Corp. The issuer changed its name to China Aoxing Pharmaceutical Co., Inc. in July 2006. The issuer then changed its name to Aoxing Pharmaceutical Company, Inc. in March, 2010

On September 16, 2022, David Duarte, a shareholder of the Company, caused demands for compliance with Florida Statutes Chapter 607 to be sent to the address listed for the Registered Agent of Aoxing, with the Florida Secretary of State. On November 4<sup>th</sup>, 2022, David Duarte filed a petition against the Company in the Eleventh Circuit Court of Miami-Dade County, Florida, entitled “In the Matter of Aoxing Pharmaceutical Company, Inc. a Florida corporation,” case number 2022-021295-CA-01.

On June 28<sup>th</sup>, 2023 the District Court of Miami-Dade County, Florida entered an Order Granting Application for Appointment of David Duarte as Custodian of the Company. Pursuant to the order, the Custodian may take any actions which are reasonable, prudent, or for the benefit of the Company and it’s shareholders including but not limited to, reinstating the Company with the state of Florida, holding a shareholders meeting, filing of disclosures with OTC Markets, filing of tax returns, disclosure of capital structure and/or business plan, and to exercise the corporate powers of the Company and its board of directors or officers.

On August 11<sup>th</sup>, 2023, the Custodian appointed David Duarte as President & CEO, Secretary, Treasurer, and Director of the Company, appointed a new Registered Agent, and reinstated the entity which brought the Company active and back into good standing with the State of Florida.

On August 11<sup>th</sup>, 2023, the Custodian increased the common Authorized Shares to 750,000,000, increased the preferred Authorized Shares to 10,000,000, and amended par value of both classes to .0001.

Subsequent to the end of the reporting period, on Sept 19<sup>th</sup>, 2023, the Custodian issued to himself 265,000,000 shares of common stock, par value .0001, for consideration of Corporate Revival Services performed.

**NOTE 2 – BASIS OF PRESENTATION AND GOING CONCERN**



### Basis of Presentation

The Company has not earned any revenues from limited principal operations. Accordingly, the Company's activities have been accounted for as those of a "Development Stage Enterprise" as set forth in Financial Accounting Standards Board Statement No. 7 ("SFAS 7"). Among the disclosures required by SFAS 7 are that the Company's financial statements be identified as those of a development stage company, and that the statements of operations, stockholders' equity (deficit) and cash flows disclose activity since the date of the Company's inception.

### Basis of Accounting

The accompanying consolidated financial statements have been prepared on the accrual basis of accounting in accordance with accounting principles accepted in the United States. All intercompany transactions have been eliminated

### Going Concern

The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the liquidation of liabilities in the normal course of business. The Company currently has no operations with an accumulated deficit of \$55,858,980 as of June 30, 2023. The Company intends to commence operations as set out below and raise the necessary funds to carry out the aforementioned strategies. The Company cannot be certain that it will be successful in these strategies even with the required funding.

These factors, among others, raise substantial doubt about the Company's ability to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty

## **NOTE 3 – SIGNIFICANT ACCOUNTING POLICIES**

### Use of Estimates

The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

### Cash and Cash Equivalents

For purposes of the statement of cash flows, cash equivalents include demand deposits, money market funds, and all highly liquid debt instruments with original maturities of three months or less

### Financial Instruments

The FASB issued ASC 820-10, Fair Value Measurements and Disclosures, for financial assets and liabilities. ASC 820-10 provides a framework for measuring fair value and requires expanded disclosures regarding fair value measurements. ASC 820-10 defines fair value as the price that would be received for an asset or the exit price that would be paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date. ASC 820-10 also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs, where available. The following summarizes the three levels of inputs required by the standard that the Company uses to measure fair value:

- Level 1: Quoted prices in active markets for identical assets or liabilities
- Level 2: Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities.
- Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

#### Concentrations and Credit Risks

The Company's financial instruments that are exposed to concentrations and credit risk primarily consist of its cash, sales, and accounts receivable. The Company places its cash and cash equivalents with financial institutions of high credit worthiness. At times, its cash and cash equivalents with a particular financial institution may exceed any applicable government insurance limits. The Company's management plans to assess the financial strength and credit worthiness of any parties to which it extends funds, and as such, it believes that any associated credit risk exposures are limited.

#### Foreign Currency Translation

The accounts of the Company are accounted for in accordance with the Statement of Financial Accounting Standards No. 52 ("SFAS 52"), "Foreign Currency Translation". The financial statements of the Company are translated into US dollars as follows: assets and liabilities at year-end exchange rates; income, expenses, and cash flows at average exchange rates; and shareholders' equity at historical exchange rate.

Monetary assets and liabilities, and the related revenue, expense, gain and loss accounts, of the Company are re-measured at year-end exchange rates. Non-monetary assets and liabilities, and the related revenue, expense, gain, and loss accounts are re-measured at historical rates. Adjustments which result from the re-measurement of the assets and liabilities of the Company are included in net income.

#### Share-Based Compensation

ASC 718, Compensation – Stock Compensation, prescribes accounting and reporting standards for all share-based payment transactions in which employee services are acquired. Transactions include incurring liabilities, or issuing or offering to issue shares, options, and other equity instruments such as employee stock ownership plans and stock appreciation rights. Share-based payments to employees, including grants of employee stock options, are recognized as compensation expense in the financial statements based on their fair values. That expense is recognized in the period of grant.

The Company accounts for stock-based compensation issued to non-employees and consultants in accordance with the provisions of ASC 505-50, Equity – Based Payments to Non-Employees. Measurement of share-based payment transactions with non-employees is based on the fair value of whichever is more reliably measurable: (a) the goods or services received; or (b) the equity instruments issued.

The fair value of the share-based payment transaction is determined at the earlier of performance commitment date or performance completion date.

As of June 30, 2023, and June 30, 2022, respectively, there was \$Nil of unrecognized expense related to non-vested stock-based compensation arrangements granted. There have been no options granted during the three months ended June 30, 2023, and 2022, respectively.

### Income Taxes

The Company accounts for income taxes under ASC 740, Income Taxes. Under the asset and liability method of ASC 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period the enactment occurs. A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations. Deferred tax assets or liabilities were offset by a 100% valuation allowance, therefore there has been no recognized benefit as of June 30, 2023, and June 30, 2022, respectively. Further it is unlikely with the change of control that the Company will have the ability to realize any future tax benefits that may exist.

### Commitments and Contingencies

The Company follows ASC 450-20, Loss Contingencies, to report accounting for contingencies. Liabilities for loss contingencies arising from claims, assessments, litigation, fines and penalties and other sources are recorded when it is probable that a liability has been incurred and the amount of the assessment can be reasonably estimated.

### Earnings Per Share

Basic EPS is calculated by dividing net income (loss) available to common stockholders by the weighted average number of shares of the Company's common stock outstanding during the period. Diluted EPS is calculated based on the net income (loss) available to common stockholders and the weighted average number of shares of common stock outstanding during the period, adjusted for the effects of all potential dilutive common stock issuances related to options, warrants, restricted stock units and convertible preferred stock. The dilutive effect of our share-based awards and warrants is computed using the treasury stock method, which assumes all sharebased awards and warrants are exercised and the hypothetical proceeds from exercise are used to purchase common stock at the average market price during the period. The incremental shares (i.e., the difference between shares assumed to be issued versus purchased), to the extent they would have been dilutive, are included in the denominator of the diluted EPS calculation. The dilutive effect of our convertible preferred stock is computed using the if-converted method, which assumes conversion at the beginning of the year. However, when a net loss exists, no potential common stock equivalents are included in the computation of the diluted per-share amount because the computation would result in an anti-dilutive per-share amount.

### Forgiveness of Indebtedness

The Company follows the guidance of AS 470.10 related to debt forgiveness and extinguishment. Debts of the Company are considered extinguished when the statute of limitations in the applicable jurisdiction expires or when terminated by judicial authority such as the granting of a declaratory judgment. Debts to related parties or shareholders are treated as capital transactions when forgiven or extinguished and credited to additional paid in capital. Debts to non-related parties are treated as other income when forgiven or extinguished.

### Recent Accounting Pronouncements

We have reviewed all the recently issued, but not yet effective, accounting pronouncements and we do not believe any of these pronouncements will have a material impact on the Company.

In August 2017, the FASB issued ASU No. 2017-12, Derivatives and Hedging (Topic 815), which changes both the designation and measurement guidance for qualifying hedging relationships and the presentation of hedge results, in order to better align an entity's risk management activities and financial reporting for hedging relationships. The amendments expand and refine hedge accounting for both nonfinancial and financial risk components and align the recognition and presentation of the effects of the hedging instrument and the hedged item in the financial statements. FASB ASU No. 2017-12 is effective for annual reporting periods beginning after December 15, 2018, including interim periods within those annual reporting periods, with early adoption permitted. We are still evaluating the impact that this guidance will have on our financial position or results of operations, and we have not yet determined whether we will early adopt FASB ASU No. 2017-12.

In March 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2016-09, Compensation – Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. This guidance changes how companies account for certain aspects of share-based payments to employees. Among other things, under the new guidance, companies will no longer record excess tax benefits and certain tax deficiencies in additional paid-in-capital ("APIC") but will instead record such items as income tax expense or benefit in the income statement, and APIC pools will be eliminated. Companies will apply this guidance prospectively. Another component of the new guidance allows companies to make an accounting policy election for the impact of forfeitures on the recognition of expense for share-based payment awards, whereby forfeitures can be estimated, as required today, or recognized when they occur. If elected, the change to recognize forfeitures when they occur needs to be adopted using a modified retrospective approach. All of the guidance will be effective for the Company in the fiscal year beginning January 1, 2018. Early adoption is permitted. The Company is currently evaluating the impact of this guidance, if any, on its financial statements and related disclosures.

In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842), which establishes new accounting and disclosure requirements for leases. FASB ASU No. 2016-02 requires lessees to classify most leases as either finance or operating leases and to initially recognize a lease liability and right-of-use asset. Entities may elect to account for certain short-term leases (with a term of 12 months or less) using a method similar to the current operating lease model. The statements of operations will include, for finance leases, separate recognition of interest on the lease liability and amortization of the right-of-use asset and for operating leases, a single lease cost, calculated so that the cost of the lease is allocated over the lease term on a straight-line basis. While we are in the early stages of our implementation process for FASB ASU No. 2016-02 and have not yet determined its impact on our financial position or results of operations, these leases would potentially be required to be presented on the balance sheet in accordance with the requirements of FASB

ASU No. 2016-02. FASB ASU No. 2016-02 is effective for annual reporting periods beginning after December 15, 2018, including interim periods within those annual reporting periods, with early adoption permitted. FASB ASU No. 2016-02 must be applied using a modified retrospective approach, which requires recognition and measurement of leases at the beginning of the earliest period presented, with certain practical expedients available.

In July 2015, the FASB issued ASU No. 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory. The guidance requires an entity to measure inventory at the lower of cost or net realizable value, which is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation, rather than the lower of cost or market in the previous guidance. This amendment applies to inventory that is measured using first-in, first-out (FIFO). This amendment is effective for public entities for fiscal years beginning after December 15, 2016, including interim periods within those years. A reporting entity should apply the amendments prospectively with earlier application permitted as of the beginning of an interim or annual reporting period. The Company is currently evaluating the impact of this guidance, if any, on its financial statements and related disclosures.

In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (“ASU 2014-09”), which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. ASU 2014-09 will replace most existing revenue recognition guidance in U.S. generally accepted accounting principles when it becomes effective. In July 2015, the FASB deferred the effective date of the standard by an additional year; however, it provided companies the option to adopt one year earlier, commensurate with the original effective date. Accordingly, the standard will be effective for the Company in the fiscal year beginning January 1, 2018, with an option to adopt the standard for the fiscal year beginning January 1, 2017. The Company is currently evaluating this standard and has not yet selected a transition method or the effective date on which it plans to adopt the standard, nor has it determined the effect of the standard on its financial statements and related disclosures.

#### **NOTE 4 – INCOME TAXES**

Income taxes are provided based upon the liability method. Under this approach, deferred income taxes are recorded to reflect the tax consequences in future years of differences between the tax basis of assets and liabilities and their financial reporting amounts at each year-end. A valuation allowance is recorded against deferred tax assets if management does not believe the Company has met the “more likely than not” standard imposed by accounting standards to allow recognition of such an asset.

Deferred tax assets/liabilities were as follows as of June 30, 2023, and June 30, 2022:

<b><u>Description</u></b>	<b>June 30, 2023</b>	<b>June 30, 2022</b>
Net operating loss carry forward	\$ -	\$ -
Valuation allowance	\$ -	\$ -
Total	\$ -	\$ -

As of June 30, 2023, and June 30, 2022, the Company expected no net deferred tax assets to be recognized, resulting from net operating loss carry forwards. Deferred tax assets were offset by a corresponding allowance of 100%.

The Company experienced a change in control during the year, and therefore no more than an insignificant portion of this net operating allowance will ever be used against future taxable income.

#### **NOTE 5 – NOTES PAYABLE AND RELATED PARTIES**

There were no convertible notes payable during the period.

#### **NOTE 6 – CONVERTIBLE NOTES PAYABLE**

There were no convertible notes payable during this period.

#### **NOTE 7 – COMMITMENTS AND CONTINGENCIES**

The Company's Operations are subject to significant risk and uncertainties including financial, operational and regulatory risks, including the potential of business failure.

#### **NOTE 8 – SUBSEQUENT EVENTS**

Subsequent to the end of reporting period, on Sept 19<sup>th</sup> 2023 the Custodian issued to himself 265,000,000 shares of common stock, par value .0001, for consideration of Corporate Revival Services performed.